prescription bottle of Harvoni and pill
Harvoni is one of the four hepatitis C drugs that will face restrictions under Gilead's new 340B contract pharmacy policy.

Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy

HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

Ryan White Clinics for 340B Access (RWC-340B) said today it “is gravely disappointed by Gilead’s recent actions to undermine Ryan White Clinics and other safety net providers’ use of the 340B program for the communities we serve.”

HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer